摘要
目的 分析HBV BCP A1762T/G1764A双突变与慢加急性肝衰竭（Acute on chronic liver failure,ACLF）之间的相关性.方法 对166名HBV慢性感染后处于疾病不同阶段的患者进行HBV前BCP A1762T/G1764A双突变检测,比较不同患者之间突变率的差异.结果 慢性肝炎（CHB）45人,肝硬化（LC）45人,ACLF 49人,肝细胞癌（HCC）27人,各组A1762T/G1764A双突变率分别为40.0%（18/45）、84.4%（38/45）、73.5%（36/49）、92.6%（25/27）.但是,以CHB为基础的ACLF患者和以LC为基础的ACLF患者A1762T/G1764A双突变率差异无统计学意义[（81.3%）vs.（69.7%）,P=0.502].HBeAg阳性者和HBeAg阴性者BCP双突变率差异无统计学意义（P=0.735）.A1762T/G1764A双突变者HBV DNA水平（10g）为5.68±1.36,阴性者HBV DNA水平（log）为6.14±1.81,差异无统计学意义（P=0.075）.结论 A1762T/G1764A双突变与HBV感染后疾病进展相关,不具备ACLF特异性;A1762T/G1764A联合突变者HBV DNA水平及HBeAg状态也与非联合突变者差异无统计学意义.
Objective To analysis the relationship between HBV BCP A1762T/G1764A double mutation with acute on chronic liver failure（ACLF）.Methods HBV BCP A1762T/G1764A double mutation was detected in 166 HBV chronic infection patients by nested PCR and direct DNA sequencing.The mutation rate was compared among the patients with different disease course.Results Among 166 patients,45 patients,45 patients,49 patients and 27 patients were diagnosed as chronic hepatitis B（CHB）,liver cirrhosis（LC）,ACLF and hepatocellular carcinoma（HCC）,respectively.A1762T/G1764A double mutation rate was 40.0%（18/45）,84.4%（38/45）,73.5%（36/49）and 92.6%（25/27） respectively in different groups.However,A1762T/G1764A double mutation rate has no difference between ACLF based on CHB and LC（P=0.502）and between patients with HBeAg positive and negative（P=0.735）.HBV DNA level （log） of patients with A1762T/G1764A double mutation was 5.68±1.36,lower than but having no significant statistic difference compared to patients without the double mutation（6.14±1.81,P=0.075）.Conclusion A1762T/G1764A double mutation has a close relationship with the progress of HBV-infection diseases,but is not specific to patients with ACLF.And patients with BCP double mutation have similar HBV DNA levels and HBeAg status with patients without the double mutation.
出处
《中华实验和临床病毒学杂志》
CAS
CSCD
北大核心
2010年第3期190-192,共3页
Chinese Journal of Experimental and Clinical Virology
基金
国家＂十一五＂科技重大专项课题项目（2008ZX10002005-6）
国家重点基础研究发展计划（973计划）,乙型肝炎重症化的发病机制、临床预警和转归的基础研究（2007CB512806）
